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Dr. Adam Berger Heads New Section of Surgical Oncology

Adam Berger, MD, FACS has been named Chief of the new Section of Surgical Oncology in the Department
of Surgery. The section’s specialty overlaps with several divisions in the Department of Surgery and
therefore includes surgeons specializing in many areas, including pancreatic cancer, breast cancer, and
thyroid cancer.
Dr. Berger is taking on this latest administrative challenge in addition to his ongoing clinical, research and
educational responsibilities. His efforts have not gone unnoticed. As a Cancer Liaison Physician at
Jefferson, Dr. Berger recently received an Outstanding Performance Award for going above and beyond
the scope of the normal duties of serving as a liaison between the Hospital’s cancer program and the
American College of Surgeons Commission on Cancer.
As Section Chief, Dr. Berger’s first task will be formalizing a surgical oncology curriculum for medical
students and residents. Jefferson will also be applying for an NIH T-32 training grant to allow one surgical
resident to be more formally trained in oncologic basic science for two years during his or her residency.
Dr. Berger will be a co-investigator on this grant.
In addition to his clinical and educational responsibilities as Section Chief, Dr. Berger is the Principal
Investigator (PI) for a number of national and international clinical studies. As a surgeon, Dr. Berger feels
a responsibility to encourage his patients to enroll in clinical trials. “We are often the first doctor that a
patient sees after his or her diagnosis, and we form a strong bond,” he says. “Part of my role is to advise
my patients and emphasize the potential impact of their involvement in clinical trials for cancer research.”
One such trial is a randomized trial of two surgical techniques for pancreaticojejunostomy (connecting
the pancreas to the jejunum) in patients undergoing a Whipple procedure, to treat cancerous tumors of
the pancreas. “There have not been a lot of randomized prospective trials on these techniques,” says Dr.
Berger, “This is the largest study to date.” So far the technique that favored invagination of the pancreas
has resulted in fewer pancreatic leaks and fewer adverse patient outcomes. Dr. Berger presented this
research at the Annual Meeting of the Southern Surgical Association in 2008.

A second trial for which Dr. Berger is a PI studies the use of a new drug– ZD6474– in combination with
chemotherapy and radiation prior to surgery for patients with esophageal cancer. Dr. Berger
conceptualized and designed the study in consultation with AstraZeneca. “Most trials report a
pathologically complete response rate of about 20 percent,” says Dr. Berger. “So far, five out of eight
patients (63 percent) in our current trial have had pathologically complete responses–meaning the tumor
has been entirely eliminated–which is very encouraging.”
Dr. Berger is also a surgical co-investigator for a multi-institutional trial through the Radiation Therapy
Oncology Group, the first Phase III trial to compare the effects of chemotherapy and radiation versus
chemotherapy alone for pancreas cancer patients following surgical removal of the head of the pancreas.
“Unlike in the United States, European physicians tend to think the combined treatments are worse for the
patient’s long-term survival and quality of life,” says Dr. Berger. Approximately 900 patients will be
enrolled, in Europe, Canada, and the United States. “This study has been a long time in the making,” says
Dr. Berger, “but the results will be groundbreaking for how we treat pancreatic cancer.”
This surgical oncology expertise is now accessible beyond the Jefferson Center City campus. Dr. Berger
provides surgical oncology services to Nazareth Hospital in Northeast Philadelphia as a part of the
Jefferson Cancer Network. The Nazareth team also includes five Jefferson medical oncologists and
radiation oncologists. Dr. Berger notes, “Our goal is to reach out and bring our first-rate care to
surrounding communities.”
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Changing Lives Through Research

On the Job
Joseph Cozzitorto, is a Research

Associate at the Jefferson Center for
Pancreatic, Biliary and Related Cancers.

How did you come to work at Jefferson?
My wife, Ellen, had been diagnosed with
pancreatic cancer, and our physician in
Princeton recommended that we come to
Jefferson for her surgery. I had worked for
25 years in the field of molecular biology,
so during one of our visits, I inquired
whether the department was doing any
research. Dr. Yeo thought my experience
was a good fit for Dr. Jonathan Brody, who
was about to establish a new lab dedicated
to pancreatic cancer. That was in 2006,
and I’ve been commuting from my home in
South Brunswick, NJ, ever since.
What did your prior experience involve?
Dr. Berger is heading the new Section of Surgical Oncology at Jefferson in Center City while
working to expand oncology services to Northeast Philadelphia through Nazareth Hospital.
At the same time, he is working on formalizing a curriculum and continuing his work on
several clinical studies.

Dr. Adam Berger Heads New
Section of Surgical Oncology
Adam Berger, MD, FACS has been named
Chief of the new Section of Surgical
Oncology in the Department of Surgery.
The section’s specialty overlaps with
several divisions in the Department of
Surgery and therefore includes surgeons
specializing in many areas, including
pancreatic cancer, breast cancer, and
thyroid cancer.

“So far, five out of eight
patients in our current trial
have had pathologically
complete responses”
Dr. Berger is taking on this latest
administrative challenge in addition to his
ongoing clinical, research and educational
responsibilities. His efforts have not gone
unnoticed. As a Cancer Liaison Physician
at Jefferson, Dr. Berger recently received
an Outstanding Performance Award for
going above and beyond the scope of
the normal duties of serving as a liaison
between the Hospital’s cancer program
and the American College of Surgeons
Commission on Cancer.
As Section Chief, Dr. Berger’s first task
will be formalizing a surgical oncology
curriculum for medical students and
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residents. Jefferson will also be applying
for an NIH T-32 training grant to allow
one surgical resident to be more formally
trained in oncologic basic science for
two years during his or her residency.
Dr. Berger will be a co-investigator on
this grant.
In addition to his clinical and educational
responsibilities as Section Chief, Dr.
Berger is the Principal Investigator (PI)
for a number of national and international
clinical studies. As a surgeon, Dr. Berger
feels a responsibility to encourage his
patients to enroll in clinical trials. “We are
often the first doctor that a patient sees
after his or her diagnosis, and we form a
strong bond,” he says. “Part of my role is
to advise my patients and emphasize the
potential impact of their involvement in
clinical trials for cancer research.”
One such trial is a randomized
trial of two surgical techniques for
pancreaticojejunostomy (connecting
the pancreas to the jejunum) in patients
undergoing a Whipple procedure, to
treat cancerous tumors of the pancreas.
“There have not been a lot of randomized
prospective trials on these techniques,”
says Dr. Berger, “This is the largest
study to date.” So far the technique that
favored invagination of the pancreas

I did Plant Molecular Biology, while
working for EniChem America, an
Italian startup company and American
Cyanamid Corporation, which specializes
in agricultural chemistry. At American
Cyanamid I isolated genes of agronomic
interest and generated mutations that
would allow plants to survive in the
presence of herbicide. I had also done
biomedical and basic research in academia
and for other companies in molecular
biology. The way I look at it is that every
other job I’ve had was a preparation for the
work I do now.

has resulted in fewer pancreatic leaks
and fewer adverse patient outcomes.
Dr. Berger presented this research at the
Annual Meeting of the Southern Surgical
Association in 2008.
A second trial for which Dr. Berger is a PI
studies the use of a new drug– ZD6474–
in combination with chemotherapy and
radiation prior to surgery for patients
with esophageal cancer. Dr. Berger
conceptualized and designed the study
in consultation with AstraZeneca.
“Most trials report a pathologically
complete response rate of about 20
percent,” says Dr. Berger. “So far, five
out of eight patients (63 percent) in our
current trial have had pathologically
complete responses–meaning the tumor
has been entirely eliminated–which is
very encouraging.”
Dr. Berger is also a surgical
co-investigator for a multi-institutional
trial through the Radiation Therapy
Oncology Group, the first Phase III trial
to compare the effects of chemotherapy
and radiation versus chemotherapy alone

What do you do in Dr. Brody’s lab?
I do cloning work, which involves isolating
certain genes from cultures of mammalian
cells or clinical samples of patient tumors
and inserting them into plasmids so that
they can be used in experiments. We
also investigate drug activity in cultured
cells that have been transfected with
these genes. I have co-authored several
articles on our findings. I also manage
the lab, which includes two residents, a
PhD investigator, a research assistant,
and volunteers. As the lab’s Principal
Investigator, Dr. Brody always has creative
ideas for experiments that keep the
projects moving forward. It’s a very teamoriented environment.

for pancreas cancer patients following
surgical removal of the head of the
pancreas. “Unlike in the United States,
European physicians tend to think the
combined treatments are worse for the
patient’s long-term survival and quality
of life,” says Dr. Berger. Approximately
900 patients will be enrolled, in Europe,
Canada, and the United States. “This
study has been a long time in the
making,” says Dr. Berger, “but the results
will be groundbreaking for how we treat
pancreatic cancer.”
This surgical oncology expertise is now
accessible beyond the Jefferson Center
City campus. Dr. Berger provides surgical
oncology services to Nazareth Hospital
in Northeast Philadelphia as a part of the
Jefferson Cancer Network. The Nazareth
team also includes five Jefferson medical
oncologists and radiation oncologists.
Dr. Berger notes, “Our goal is to reach
out and bring our first-rate care to
surrounding communities.”
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